for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aarti Drugs Ltd.

ADRG.NS

Latest Trade

478.95INR

Change

13.45(+2.89%)

Volume

62,127

Today's Range

468.65

 - 

483.40

52 Week Range

427.00

 - 

707.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
465.50
Open
468.65
Volume
62,127
3M AVG Volume
0.31
Today's High
483.40
Today's Low
468.65
52 Week High
707.00
52 Week Low
427.00
Shares Out (MIL)
23.30
Market Cap (MIL)
10,846.15
Forward P/E
10.19
Dividend (Yield %)
0.21

Next Event

Q2 2020 Aarti Drugs Ltd Earnings Release

Latest Developments

More

India's Aarti Drugs June Quarter Consol Net Profit Falls

India's Aarti Drugs Dec Qtr Consol Profit Falls

India's Aarti Drugs Sept-Qtr Consol Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aarti Drugs Ltd.

Aarti Drugs Limited is a pharmaceutical company. The Company offers active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins. Its products under APIs include Aceclofenac, Diclofenac Potassium, Diclofenac Diethylamine, Clopidogrel Bisulphate and Telmisartan. Its pharma intermediates include Antiprotozoal, Celecoxib, Antibiotic, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Zolpidem and Telmisartan. It also offers specialty chemicals, such as Benzene Sulphonamide, Benzene Sulphonic acid methyl ester, Benzene Sulphonyl chloride, Methyl Nicotinate, N-Methyl Methane Sulphonamide, Ortho para toluene Sulphonamide, Ortho/para toluene Sulphonic acid methyl ester, Para chloro benzene sulphonamide, Para Toluene Sulphonic acid methyl ester and Para Toluene Sulphonyl Chloride. Pinnacle Life Science Private Limited is the subsidiary of the Company.

Industry

Biotechnology & Drugs

Contact Info

Block No1 & 12 To 16

Village Karanj, Tal Mandvi

+91.22.24019025

http://www.aartidrugs.co.in/

Executive Leadership

Prakash M. Patil

Executive Chairman of the Board, Chief Executive Officer, Managing Director

Chandrakant Vallabhaji Gogri

Chairman Emeritus

Rushikesh Deole

Compliance Officer, Company Secretary

Harshit M. Savla

Joint Managing Director, Executive Director

Rashesh C. Gogri

Managing Director, Executive Director

Key Stats

1.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

12.0K

2018

12.4K

2019

15.6K

2020(E)

18.0K
EPS (INR)

2017

33.400

2018

34.410

2019

38.480

2020(E)

45.680
Price To Earnings (TTM)
12.34
Price To Sales (TTM)
0.68
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
8.17
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

BRIEF-Aarti Drugs Says Unit Affected Due To Explosion In Adjoining Unit In Tarapur

* SAYS CO'S UNIT ADVERSELY AFFECTED DUE TO MASSIVE EXPLOSION IN ADJOINING UNIT E-107 OF NOVAPHENE SPECIALTIES IN TARAPUR

BRIEF-India's Aarti Drugs Dec-Qtr Consol Profit Rises

* DEC QUARTER CONSOL PROFIT 233.3 MILLION RUPEES VERSUS PROFIT 178.5 MILLION RUPEES YEAR AGO

BRIEF-India's Aarti Drugs Approves Buyback Of Equity Shares

* SAYS BUYBACK OF EQUITY SHARES WORTH UP TO 240.6 MILLION RUPEES Source text - http://bit.ly/2m7c2c3 Further company coverage:

BRIEF-Aarti Drugs To Consider Proposal Of Buyback Of Fully Paid-Up Equity Shares Of Co

* TO CONSIDER PROPOSAL OF BUYBACK OF FULLY PAID-UP EQUITY SHARES OF CO Source text for Eikon: Further company coverage:

BRIEF-India's Aarti Drugs Sept-qtr profit falls

* Sept quarter profit 180.3 million rupees versus 201 million rupees year ago

BRIEF-India's Aarti Drugs June-qtr profit falls

* June quarter profit 105.7 million rupees versus profit 173.4 million rupees year ago

BRIEF-India's Aarti Drugs March-qtr consol profit rises

* March quarter consol net profit 207.3 million rupees versus profit 185.9 million rupees year ago

BRIEF-Aarti Drugs gets closure directions for Tarapur unit

* Says Maharasthra Pollution Control Board issed closure directions unit in Tarapur

BRIEF-Aarti Drugs Dec-qtr consol profit rises

* Dec quarter consol net profit 178.5 million rupees versus 170.3 million rupees year ago

BRIEF-Aarti Drugs approves buyback of shares worth 270 million rupees

* Aarti Drugs says approves buyback of shares worth 270 million rupees Source text : http://bit.ly/2egmrQS Further company coverage: (Bengaluru newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up